MAPT and Alzheimer disease: Acetylation of tau at lysine 280 has been recognized as a significant determinant of the molecular etiology of AD.[89] Emerging scholarly investigations have provided compelling evidence that tau acetylation may precede tau hyperphosphorylation, thus potentially serving as the primary catalyst for neuronal degeneration in the early stages of AD.